Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrice Barlesi

Showing results (11-20 of 343) with videos related to

Pageof 35
Sort By:
British Journal of Cancer|June 17, 2020
Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTICJoseph Ciccolini, Sébastien Benzekry, Fabrice Barlesi
Therapeutic Advances in Respiratory Disease|June 25, 2016
Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experienceLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Cancer|June 1, 2026
Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going?Claudia Parisi, Fabrice Barlesi, David Planchard
JAMA Oncology|April 1, 2021
Patient Willingness to Enroll in Cancer Clinical Trials When Sites Return to Prepandemic StatusArnaud Bayle, Fabrice Barlesi, Christophe Massard
Translational Lung Cancer Research|December 4, 2018
The clinical utility of tumor mutational burden in non-small cell lung cancerLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 25, 2018
Another Drawback for Clinical Trials Entry CriteriaMaeva Andriantsoa, Mathieu Barbolosi, Fabrice Barlesi
Translational Lung Cancer Research|May 19, 2020
Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?Camille Travert, Pascale Tomasini, Fabrice Barlesi
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2018
Specialists to the Rescue of Oncologists for the Management of Toxicity Occurring Under Combination of Anticancer TherapiesThomas Chevalier, Stéphane Burtey, Fabrice Barlesi
Expert Opinion on Biological Therapy|June 9, 2015
Necitumumab for non-small cell lung cancerLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Annals of Translational Medicine|July 19, 2016
Elderly selection on geriatric index assessmentPascale Tomasini, Celine Mascaux, Fabrice Barlesi
Pageof 35

Showing results (11-20 of 343) with videos related to

Sort By:
Pageof 35
British Journal of Cancer|June 17, 2020
Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTICJoseph Ciccolini, Sébastien Benzekry, Fabrice Barlesi
Therapeutic Advances in Respiratory Disease|June 25, 2016
Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experienceLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Cancer|June 1, 2026
Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going?Claudia Parisi, Fabrice Barlesi, David Planchard
JAMA Oncology|April 1, 2021
Patient Willingness to Enroll in Cancer Clinical Trials When Sites Return to Prepandemic StatusArnaud Bayle, Fabrice Barlesi, Christophe Massard
Translational Lung Cancer Research|December 4, 2018
The clinical utility of tumor mutational burden in non-small cell lung cancerLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 25, 2018
Another Drawback for Clinical Trials Entry CriteriaMaeva Andriantsoa, Mathieu Barbolosi, Fabrice Barlesi
Translational Lung Cancer Research|May 19, 2020
Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?Camille Travert, Pascale Tomasini, Fabrice Barlesi
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2018
Specialists to the Rescue of Oncologists for the Management of Toxicity Occurring Under Combination of Anticancer TherapiesThomas Chevalier, Stéphane Burtey, Fabrice Barlesi
Expert Opinion on Biological Therapy|June 9, 2015
Necitumumab for non-small cell lung cancerLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Annals of Translational Medicine|July 19, 2016
Elderly selection on geriatric index assessmentPascale Tomasini, Celine Mascaux, Fabrice Barlesi
Pageof 35